Compounds > rosiglitazone
Page last updated: 2024-08-25

rosiglitazone and Cardiac Diseases

rosiglitazone has been researched along with Cardiac Diseases in 12 studies

Research

Studies (12)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's7 (58.33)29.6817
2010's5 (41.67)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Huang, Q; Li, D; Li, T; Li, Z; Lu, Y; Pan, Z; Wu, H; Yang, T; Yang, W; Zhan, L; Zhang, G; Zhuang, Y1
Blaner, WS; Drosatos, K; Goldberg, IJ; Homma, S; Jiang, H; Khan, RS; Schulze, PC; Son, NH; Trent, CM1
Mishra, P; Rath, SK; Singh, SV; Srivastava, P; Sultana, S; Verma, AK1
Faich, GA; Stemhagen, A1
Ambery, P; Pandya, B1
Finck, BN; Gropler, RJ; Herrero, P; Schechtman, KB; Sharp, T; Shoghi, KI; Welch, MJ1
Gautier, JF; Lesven, S; Maréchaud, R1
Le Feuvre, C1
De Flines, J; Paquot, N; Scheen, AJ1
D'Arrigo, T1

Reviews

3 review(s) available for rosiglitazone and Cardiac Diseases

ArticleYear
Treatment of type 2 diabetes: New clinical studies and effects of GLP-1 on macrovascular complications.
    Annales d'endocrinologie, 2010, Volume: 71, Issue:6

    Topics: Animals; Coronary Artery Disease; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Glucagon-Like Peptide 1; Heart Diseases; Humans; Hypoglycemic Agents; Risk Factors; Rosiglitazone; Thiazolidinediones

2010
[Heart, diabetes and glitazones].
    Annales d'endocrinologie, 2004, Volume: 65, Issue:1 Suppl

    Topics: Contraindications; Diabetes Mellitus, Type 2; Edema; Heart; Heart Diseases; Humans; Hypoglycemic Agents; Insulin Resistance; Rosiglitazone; Thiazolidinediones

2004
[What about the controversy regarding rosiglitazone].
    Revue medicale de Liege, 2007, Volume: 62, Issue:9

    Topics: Advisory Committees; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Heart Diseases; Humans; Hypoglycemic Agents; Risk Assessment; Rosiglitazone; Thiazolidinediones; United States; United States Food and Drug Administration

2007

Other Studies

9 other study(ies) available for rosiglitazone and Cardiac Diseases

ArticleYear
Involvement of lncR-30245 in Myocardial Infarction-Induced Cardiac Fibrosis Through Peroxisome Proliferator-Activated Receptor-γ-Mediated Connective Tissue Growth Factor Signalling Pathway.
    The Canadian journal of cardiology, 2019, Volume: 35, Issue:4

    Topics: Animals; Benzamides; Cell Proliferation; Collagen; Connective Tissue Growth Factor; Fibroblasts; Fibrosis; Heart Diseases; Mice, Inbred C57BL; Models, Animal; Myocardial Infarction; PPAR gamma; Pyridines; RNA, Long Noncoding; Rosiglitazone; Stroke Volume; Transforming Growth Factor beta1; Up-Regulation

2019
Peroxisome proliferator-activated receptor-γ activation prevents sepsis-related cardiac dysfunction and mortality in mice.
    Circulation. Heart failure, 2013, Volume: 6, Issue:3

    Topics: Animals; Fatty Acids; Heart Diseases; Mice; Mice, Inbred C57BL; Mice, Transgenic; Myocardium; PPAR gamma; Rosiglitazone; Sepsis; Thiazolidinediones; Ventricular Dysfunction, Left

2013
Rosiglitazone induces cardiotoxicity by accelerated apoptosis.
    Cardiovascular toxicology, 2014, Volume: 14, Issue:2

    Topics: Animals; Antioxidants; Apoptosis; Biomarkers; Cell Differentiation; Cell Line; Cell Survival; Diabetes Mellitus; Disease Models, Animal; Dose-Response Relationship, Drug; Gene Expression Regulation; Heart Diseases; Heme Oxygenase (Decyclizing); Hypoglycemic Agents; Male; Mice; Myocytes, Cardiac; NADPH Oxidases; NF-E2-Related Factor 2; Nitric Oxide Synthase; Oxidative Phosphorylation; Oxidative Stress; Protein Kinase C-delta; Rats; Rosiglitazone; Signal Transduction; Superoxides; Thiazolidinediones; Time Factors

2014
Cardiac safety of diabetes therapies and postmarketing requirements.
    Pharmacoepidemiology and drug safety, 2008, Volume: 17, Issue:8

    Topics: Heart Diseases; Humans; Hypoglycemic Agents; Product Surveillance, Postmarketing; Risk Assessment; Rosiglitazone; Thiazolidinediones

2008
The new rosiglitazone story: its place today in type 2 diabetes management.
    Primary care diabetes, 2009, Volume: 3, Issue:1

    Topics: Administration, Oral; Blood Glucose; Diabetes Mellitus, Type 2; Evidence-Based Medicine; Heart Diseases; Humans; Hypoglycemic Agents; Patient Selection; Practice Guidelines as Topic; Risk Assessment; Rosiglitazone; Thiazolidinediones; Treatment Outcome

2009
In vivo metabolic phenotyping of myocardial substrate metabolism in rodents: differential efficacy of metformin and rosiglitazone monotherapy.
    Circulation. Cardiovascular imaging, 2009, Volume: 2, Issue:5

    Topics: Animals; Biological Transport; Diabetes Mellitus, Type 2; Disease Models, Animal; Echocardiography; Energy Metabolism; Fatty Acids; Gene Expression Regulation; Glucose; Glucose Transport Proteins, Facilitative; Heart Diseases; Hemodynamics; Hypoglycemic Agents; Male; Metformin; Myocardium; Oxidation-Reduction; Phenotype; Positron-Emission Tomography; Rats; Rats, Zucker; Rosiglitazone; Thiazolidinediones; Time Factors

2009
Alternative medications exist for controversial diabetes drug. Patients concerned about rosiglitazone (Avandia) should talk with their doctors about other options.
    Heart advisor, 2010, Volume: 13, Issue:10

    Topics: Diabetes Mellitus, Type 2; Heart Diseases; Humans; Hypoglycemic Agents; Product Surveillance, Postmarketing; Rosiglitazone; Thiazolidinediones

2010
Protecting the heart while controlling blood sugar. New guidelines help define and refine the use of two diabetes drugs that could be a boon for people who also have heart disease.
    Harvard heart letter : from Harvard Medical School, 2004, Volume: 14, Issue:7

    Topics: Contraindications; Diabetes Mellitus; Diabetic Angiopathies; Heart Diseases; Heart Failure; Humans; Hypoglycemic Agents; Pioglitazone; Rosiglitazone; Thiazolidinediones

2004
Glitazones and your heart, revisited.
    Diabetes forecast, 2007, Volume: 60, Issue:13

    Topics: Heart Diseases; Heart Failure; Humans; Pioglitazone; Rosiglitazone; Thiazolidinediones

2007